Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dubermatinib in advanced solid tumors
NCT02729298Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2016
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dubermatinib in solid tumor, non-small cell lung cancer (NSCLC), colorectal carcinoma (CRC) and 2 more (6 arms), sponsored by Sumitomo Pharma America. Primary endpoints: Incidence of dose-limiting toxicities and Treatment emergent adverse events. Started Dec 2016; status: completed.
02
Drugs
dubermatinib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal carcinoma (CRC)ovarian cancermelanoma
Beyond the preview
Go deeper on NCT02729298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02729298.